Tacrolimus 0.1% Topical Ointment
Targets non-steroidal macrolide calcineurin / nfat t-cell inhibitor pathways to control symptoms and support evidence-based outpatient management.
Toggle your prescriptions and supplements below to see stomach mineral absorption blocks, CYP450 conflicts, and your exact 24-hour clock:
Take 30–60 min before coffee/breakfast; keep 4 hours away from Iron, Calcium & Magnesium.
Alternate-day morning dosing with 200 mg Vitamin C avoids the 24h hepcidin block and protects Levothyroxine.
Avoid potassium chloride salt substitutes or high-dose potassium supplements (hyperkalemia >5.2 mEq/L risk).
Fat-soluble D3, K2 (MK-7), Omega-3 rTG, and CoQ10 Ubiquinol absorb 32%–50% better with dietary fat.
Taking Extended-Release (ER) mid-dinner cuts GI nausea/diarrhea by >60%. Check Vitamin B12 + MMA yearly.
Pairs cleanly with dinner alongside CoQ10 Ubiquinol (100–200 mg) to support muscle mitochondrial ATP.
Safely separated 15 hours from morning Levothyroxine; glycine + Mg2+ support GABAergic deep sleep.
Never pay a $45–$68 retail pharmacy walk-in markup for pennies-per-pill generics:
Targets non-steroidal macrolide calcineurin / nfat t-cell inhibitor pathways to control symptoms and support evidence-based outpatient management.
Relaxes smooth muscle via cGMP or alpha-1A blockade to restore vascular flow and lower urinary tract symptoms.
Relaxes smooth muscle via cGMP or alpha-1A blockade to restore vascular flow and lower urinary tract symptoms.
Regulates follicular keratinization, sebum production, or scalp DHT activity over 8–16 weeks.
Lowers systolic and diastolic blood pressure over 2–4 weeks to protect vascular, cardiac, and kidney tissue.
Targets allylamine fungal squalene epoxidase fungicidal inhibitor pathways to control symptoms and support evidence-based outpatient management.
Targets esterified parenteral androgen receptor agonist pathways to control symptoms and support evidence-based outpatient management.
Targets natural porcine thyroglobulin t4 + t3 combination pathways to control symptoms and support evidence-based outpatient management.
Achieves 20.9% mean weight reduction at 72 weeks (SURMOUNT-1) and cuts prediabetes-to-T2D progression by 94% over 3 years.
Regulates follicular keratinization, sebum production, or scalp DHT activity over 8–16 weeks.
Targets sulfamate-substituted monosaccharide ampa/na+/gaba/carbonic anhydrase modulator pathways to control symptoms and support evidence-based outpatient management.
Targets synthetic lysine-binding antifibrinolytic & keratinocyte plasmin inhibitor pathways to control symptoms and support evidence-based outpatient management.
Modulates central monoamine neurotransmission over 2–6 weeks to stabilize anxiety, mood, and resilience.
Regulates follicular keratinization, sebum production, or scalp DHT activity over 8–16 weeks.
Targets calcineurin inhibitor immunosuppressant pathways to control symptoms and support evidence-based outpatient management.
Targets calcineurin inhibitor immunosuppressant pathways to control symptoms and support evidence-based outpatient management.
Targets fda prescription monograph pathways to control symptoms and support evidence-based outpatient management.
Targets prostaglandin analog pathways to control symptoms and support evidence-based outpatient management.
Targets prostaglandin analog pathways to control symptoms and support evidence-based outpatient management.
Targets cd123 interaction pathways to control symptoms and support evidence-based outpatient management.
Targets poly(adp-ribose) polymerase inhibitor pathways to control symptoms and support evidence-based outpatient management.
Targets estrogen agonist/antagonist pathways to control symptoms and support evidence-based outpatient management.
Lowers systolic and diastolic blood pressure over 2–4 weeks to protect vascular, cardiac, and kidney tissue.
Targets opioid agonist pathways to control symptoms and support evidence-based outpatient management.
Targets aryl hydrocarbon receptor agonist pathways to control symptoms and support evidence-based outpatient management.
Targets melatonin receptor agonist pathways to control symptoms and support evidence-based outpatient management.
Inhibits microbial cell-wall, ribosomal, or viral polymerase replication to clear targeted infections.
Targets methyltransferase inhibitor pathways to control symptoms and support evidence-based outpatient management.
Targets leukocyte growth factor pathways to control symptoms and support evidence-based outpatient management.
Targets bispecific gp100 peptide-hla-directed cd3 t cell engager pathways to control symptoms and support evidence-based outpatient management.
Targets fda prescription monograph pathways to control symptoms and support evidence-based outpatient management.
Targets fda prescription monograph pathways to control symptoms and support evidence-based outpatient management.
Targets orthopoxvirus vp37 envelope wrapping protein inhibitor pathways to control symptoms and support evidence-based outpatient management.
Inhibits microbial cell-wall, ribosomal, or viral polymerase replication to clear targeted infections.
Targets glp-2 analog pathways to control symptoms and support evidence-based outpatient management.
Inhibits microbial cell-wall, ribosomal, or viral polymerase replication to clear targeted infections.
See exact ACC/AHA blood pressure stages, ADA HbA1c thresholds, and step-up treatment ladders across 40 specialty hubs.
Check when statins, Metformin, or PPIs deplete CoQ10, Vitamin B12, or Magnesium—and how to decode elemental supplement labels.
Find board-certified endocrinologists, cardiologists, and internists verified by CMS Medicare Part B volume and accepted insurance plans.
dotMD.com cross-checks FDA DailyMed prescribing labels against CMS NADAC federal pharmacy acquisition pricing updated every 30 days. Generic retail quotes regularly run 8x to 40x above wholesale ($0.45–$2.85 per 30 days), letting patients compare transparent cash pricing, ER vs. IR tolerability, and boxed warnings with 0% pharma sponsorship.
| Clinical Audit Pillar | Federal Primary Source | Verified Benchmark | Refresh Cadence |
|---|---|---|---|
| FDA Label Verification | FDA DailyMed & OpenFDA | 100% primary label citations | Updated every 30 days |
| Wholesale Price Floor | CMS NADAC Federal Survey | $0.45–$2.85 typical 30-day generic | 8x–40x below cash retail |
| Tolerability & Timing | PubMed Phase 3–4 Trials | Up to 50% GI drop with ER/food | Verified trial cohorts |
| Safety & Monitoring | FDA FAERS & Guidelines | Kidney, liver & B12 lab cutoffs | Every 90–180 days |
dotMD.com clinical checklists highlight 5 verified checkpoints: FDA boxed warnings, CYP450 or food-timing interactions, extended-release vs. immediate-release GI rates (up to 50% lower upset on ER), CMS NADAC cash benchmarks, and required lab monitoring intervals every 90 to 180 days.
Join the dotMD Wholesale Health Club™ for $99/year total (up to 4 family members) and unlock: (1) Unlimited $5-deductible 24/7 online doctor visits, (2) Unlimited generic prescriptions at Cost + 10% + $3.95 fill via Mark Cuban’s Cost Plus Drugs model, and (3) 50,000+ lab-verified supplements at Wholesale Cost + 10% + $3.95 fill.